Journal News

Proteomics study isolates drug targets

Oluwadamilola “Dami” Oke
March 12, 2024

Target identification is a major stage of early drug development — the point when researchers identify a biological element implicated in a disease that can be regulated by a therapeutic agent. 

One research team in Germany has recently focused on myeloid-derived suppressor cells, or MDSCs, which are blood cells that are not fully differentiated. These cells suppress immune cell activities and promote cancer, infection, and inflammatory diseases. By screening MDSCs from mice, the researchers took the first step in identifying potential targets that can modulate MDSC activity.

Protein Data Bank
Acylphosphatase 1 (ACYP1), one of the potential drug target proteins identified for attacking myeloid-derived suppressor cells.

Johannes Krumm, a scientist at OmicScouts GmbH, and Bernhard Küster, a professor at the Technical University of Munich, collaborated with the pharmaceutical firm Merck & Co. on the study. They recently published their findings in the journal Molecular & Cellular Proteomics.

The research team used high throughput screening, a technique that allowed them to cross-test large quantities of compounds against several factors to identify potential drug targets. The screening narrowed the potential targets from 20,818 compounds in the MDSC mice cells to 104 compounds that also modulated MDSC activity in human cells.

Krumm and Küster both hope that this paper “motivates further research groups and biotech/pharma companies to consider proteomics as a tool for drug discovery,” they wrote in an email.

Proteomics combines biological assays and computer software to analyze large numbers of proteins and their associated interactions. This characterization explores the whole data set and can uncover patterns that merit further investigation.

“The strong point about proteomics is that no initial hypothesis is needed,” Krumm and Küster wrote.

In this study, their data showed that an unknown compound suppressed MDSC activity in the mice cells. They tested this compound in immunoassays with human cells where its immune activity ranged from no effect to strong effect. Following a round of proteomic analysis, they found that the active compound upregulated the expression of proteins responsible for cell detoxification; this led to a reduction in reactive oxygen species, which play a role in promoting various diseases, including cancer. By studying this pattern, the researchers determined that a strong potential mechanism of action for new drugs to modulate MDSC activity would be to upregulate proteins that reduce reactive oxygen species.

“We were rather surprised to see how selectively the active compound upregulated proteins associated with detoxification functions,” Krumm and Küster wrote.

In their analysis, they found two proteins that closely upregulated MDSC activity: Acylphosphatase 1, also known as ACYP1, and a HLA class II histocompatibility antigen gamma chain protein, also known as CD74.

In the future, drug developers looking to target MDSC immunosuppression can target the downregulation of ACYP1 and CD74 to attack MDSCs. This study is “a good example for how proteomics can be used for drug discovery in general and in mode of action hypothesis in particular,” Krumm and Küster wrote.

“By making all data available to the public,” they concluded, “we hope that biologists in the field of MDSC will find our data and chemical tool compounds useful and enriching to their own research.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Oluwadamilola “Dami” Oke

Oluwadamilola “Dami” Oke is a Ph.D. candidate of biomedical engineering at the George Washington University with an interest in communication and outreach for science advancement. She is an ASBMB Today contributing writer.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Mapping the placenta’s hormone network
Journal News

Mapping the placenta’s hormone network

Oct. 21, 2025

Study uncovers how the placenta actively metabolizes not only glucocorticoids but also novel androgens and progesterones, reshaping our understanding of pregnancy and its complications.

Biochemists and molecular biologists sweep major 2025 honors
News

Biochemists and molecular biologists sweep major 2025 honors

Oct. 20, 2025

Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.

Spider-like proteins spin defenses to control immunity
News

Spider-like proteins spin defenses to control immunity

Oct. 17, 2025

Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.